UK: EPO Oppositions Newsletter - Surge In Oppositions Matches Surge In Grants

In 2017 the number of EP patents opposed was 30% higher than in 2016.

The increase in EP patents opposed in 2017 follows extraordinary increases in EP patent grants in 2016 and 2017.

Typically, if EP patents are opposed, they are opposed at the end of the 9-month EPO opposition term. The chart below compares numbers of EP patents opposed in quarter years with numbers of patents granted 9 months (3 quarter-years) earlier. The patterns of patents opposed and earlier grants correlate rather well.

As the chart above shows, grants fell in the first quarter of 2017. The chart below shows that grants then increase in the second and third quarters of 2017. This suggests an increase in patents opposed 9 months later.

Opposed patents, opposed patentees

The patents opposed in 2017 belonged to about 1700 patentees. Around two thirds of those patentees had each only one patent opposed, only about one third had 2 or more patents opposed. The patentees listed below were the most opposed, with 750 opposed patents in total – 20% of all patents opposed in 2017.

Opposed patentee No of patents opposed 2017
Procter & Gamble 51
BASF 40
GE 40
Siemens 38
Unilever 27
Nestec S.A. 25
Honeywell 24
Borealis 23
BSH Hausgeräte 22
Dow 21
Mahle 21
Robert Bosch 21
United Technologies 21
Continental 19
Evonik 19
Krones AG 18
Philip Morris Products 18
Electrolux 17
Saint-Gobain 17
Bayer 16
Henkel 16
Krauss-Maffei 15
Mitsubishi 15
Amgen 14
Colgate-Palmolive 14
L'Oréal 14
Roche 14
Valeo 14
3M 13
CLAAS 13
Dürr Systems 13
ABB 12
Abbott 12
Giesecke & Devrient 12
KCI Licensing, Inc. 12
Knorr-Bremse 12
Merck 12
N.V. Nutricia 12
ThyssenKrupp 12

The 6 patents listed below were the most opposed EP patents in 2017, each receiving 10 or more oppositions.

Patent no. Opponents Patentee/title
2425821 Develco Pharma Schweiz AG Hexal AG/Sandoz International Glenmark Pharmaceuticals Europe KRKA, d.d., Novo mesto
Acino Pharma AG Ethypharm
G. L. Pharma GmbH STADA Arzneimittel Intas Pharmaceuticals
Teva Pharmaceutical Industries Ltd Zentiva, k.s.
EURO-CELTIQUE
S.A. et al

Pharmaceutical preparation containing oxycodone and naloxone
2425824 Develco Pharma Schweiz AG Hexal AG/Sandoz International Glenmark Pharmaceuticals Europe KRKA, d.d., Novo mesto
Acino Pharma AG Ethypharm
G. L. Pharma GmbH STADA Arzneimittel Intas Pharmaceuticals
Teva Pharmaceutical Industries Ltd Zentiva, k.s.
EURO-CELTIQUE
S.A. et al

Pharmaceutical preparation containing oxycodone and naloxone
2425825 Develco Pharma Schweiz AG KRKA, d.d., Novo mesto Acino Supply AG
Hexal AG / Sandoz International Glenmark Pharmaceuticals Europe STADA Arzneimittel
Teva Pharmaceutical Industries Ltd Intas Pharmaceuticals Ltd.
G. L. Pharma GmbH Ethypharm
EURO-CELTIQUE
S.A. et al

Pharmaceutical preparation containing oxycodone and naloxone
2175884 Mathys & Squire LLP Bristol-Myers Squibb Company
Agenus Inc. Ablynx N.V.
F. Hoffmann-La Roche AG PFIZER LIMITED
European Oppositions Limited Hoffmann Eitle
James Poole Limited Merck Sharp & Dohme
GITR, Inc.

Combination therapies employing GITR binding molecules
2752189 Glas, Holger STADA Arzneimittel AG BOEHRINGER INGELHEIM Ares Trading S.A. Generics [UK] Dehmel & Bettenhausen Hoffmann Eitle Dr. H. Ulrich Dörries Stolmár, Matthias Pfizer, Inc. F. Hoffmann-La Roche AG

Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
2940044 Hexal AG Ares Trading S.A. Pajaro Limited Samsung Bioepis UK Limited Biogen Inc. Kilger, Christian Generics [U.K.] Limited Amgen Inc. Pfizer Inc. STADA Arzneimittel AG AbbVie Biotechnology Ltd

Anti-TNF alpha antibodies for use in therapy

Opposed patents, technical fields

Each patent is classified according to the International Patent Classification (IPC), often being assigned to more than one IPC category (subclass, main group, subgroup). The patent will, however, have a lead or first IPC category which we take to be the most overall relevant for the invention concerned. Considering lead IPC subclasses, the patents opposed in 2017 were spread across about 400 subclasses. The top 10 lead subclasses are listed below. Around 850 opposed patents – almost 25% of opposed patents - had these lead subclasses.

Lead IPC subclass No of patents
A61K 288 Medical, dental, or toilet preparations
A61F 98 Stents, implants, prostheses etc.
C12N 70 Microorganisms or Enzymes;
A23L 68 Foodstuffs
B65D 68 Containers for storage or transport of articles
C08L 58 Compositions of macromolecular compounds
F03D 57 Wind motors
B29C 53 Shaping or joining of plastics
C07C 49 Acyclic or carbocyclic compounds
C11D 48 Detergent compositions

More generally, taking the IPC sections to which the lead subclasses belong, the opposed patents were spread across the IPC sections as listed below.

IPC section
A 936 Human necessities
B 785 Preforming operations; transporting
C 773 Chemistry; metallurgy
D 93 Textiles; paper
E 131 Fixed constructions
F 436 Mechanical engineering; lighting; heating; weapons; blasting
G 208 Physics
H 238 Electricity

Oppositions, opponents

The patents opposed in 2017 were subject to around 4500 oppositions, an average of 1.25 oppositions per opposed patent.

The oppositions were filed by about 1700 opponents. Around 1000 opponents each filed only one opposition. The opponents listed below were the most active, with a total of just short of 1000 oppositions filed – 20+% of all oppositions filed in 2017.

Opponent Oppositions filed 2017
Siemens 80
Henkel 71
Teva 49
BASF 45
Arkema 43
Giesecke & Devrient 42
Generics (U.K.) Ltd 40
ThyssenKrupp 40
Procter & Gamble 39
Strawman Limited 37
Valeo 34
Enercon 33
Hexal AG 33
Vestas Wind Systems 32
STADA Arzneimittel 29
Nestec S.A. 28
Knorr-Bremse 26
Mahle International 26
SCA Hygiene Products 26
N.V. Nutricia 25
Roche 24
Dow 24
Saint-Gobain 23
United Technologies 23
Evonik 22
Hoffmann Eitle 22
Borealis 21
Boston Scientific 21
VRI-Verband der Reibbelagindustrie e.V. 21

"Straw man" opponents

Some opponents are "straw man" opponents, i.e. parties who file oppositions on behalf of others. In general this is not considered to offend against EPO rules, though it is not always permissible. There are many reasons why the other parties, the principals, might wish to conceal their identities and act through "straw men". For instance, a principal may wish to conceal its interest in a particular patent or technology from a competitor (which might be the patent proprietor, another opponent or an interested party who may be watching the EPO register for opposition cases). A principal may wish to avoid direct and public confrontation with the patent proprietor in order to preserve an existing trading relationship or some other form of ongoing commercial collaboration or negotiation. Of course it is not possible to identify "hidden" straw men but it seems that approaching 200 more or less overt straw men (e.g. individual patent attorneys, patent attorney firms, law firms) were opponents in 2017 and filed over 400 oppositions - not far short of 10% of all 2017 oppositions.

Outcomes of opposition proceedings

According to the EPO Annual Report for 2017, 4072 opposition cases were decided in the first instance in that year. According to the Annual Report the first-instance outcomes in 2017 were:

First-instance outcomes of opposition proceedings
Patent maintained as granted (opposition rejected) 1262 31%
Patent maintained in amended form 1710 42%
Patent revoked 1099 27%

First-instance opposition decisions are not the whole story, since they are often appealed.

A total of over 3100 opposition proceedings were finally settled in 2017 - either as the outcome after appeal or, if no appeal was entered, when the first-instance decision became legally binding. There were 6 cases in which oppositions were deemed not filed, two in which oppositions were found to be inadmissible and 234 cases in which opposition proceedings were terminated without a decision (e.g. oppositions withdrawn). For cases decided on the merits in 2017, the final outcomes were:

Final outcomes of opposition proceedings
Patent maintained as granted (opposition rejected) 704 24%
Patent maintained in amended form 1121 39%
Patent revoked 1056 37%

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions